Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free HLS Stock Alerts

HLS Therapeutics (HLS) Competitors

HLS Therapeutics logo
C$4.71 0.00 (0.00%)
As of 04:00 PM Eastern
Compare

HLS vs. CPH, ACB, SUGR, OGI, and FIRE

Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), SugarBud Craft Growers (SUGR), Organigram (OGI), and Supreme Cannabis (FIRE). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

HLS Therapeutics has a beta of 0.392903, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 0.725282, suggesting that its stock price is 27% less volatile than the S&P 500.

5.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cipher Pharmaceuticals has a net margin of 54.37% compared to HLS Therapeutics' net margin of -22.34%. Cipher Pharmaceuticals' return on equity of 24.23% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-22.34% -19.40% -2.89%
Cipher Pharmaceuticals 54.37%24.23%7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.50M2.65-C$15.53M-C$0.39N/A
Cipher PharmaceuticalsC$50.45M9.07C$11.41MC$1.0517.25

In the previous week, HLS Therapeutics and HLS Therapeutics both had 2 articles in the media. HLS Therapeutics' average media sentiment score of 0.30 beat Cipher Pharmaceuticals' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HLS Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cipher Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 9 of the 12 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$373.12M0.74-C$44.16M-C$1.50N/A
HLS TherapeuticsC$55.50M2.65-C$15.53M-C$0.39N/A

Aurora Cannabis has a beta of 0.40301, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 0.392903, meaning that its stock price is 61% less volatile than the S&P 500.

4.2% of Aurora Cannabis shares are held by institutional investors. Comparatively, 5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aurora Cannabis has a net margin of -1.69% compared to HLS Therapeutics' net margin of -22.34%. Aurora Cannabis' return on equity of -1.15% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-1.69% -1.15% -1.87%
HLS Therapeutics -22.34%-19.40%-2.89%

In the previous week, HLS Therapeutics had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 2 mentions for HLS Therapeutics and 1 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.90 beat HLS Therapeutics' score of 0.30 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HLS Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aurora Cannabis currently has a consensus price target of C$9.25, indicating a potential upside of 96.81%. HLS Therapeutics has a consensus price target of C$6.00, indicating a potential upside of 27.39%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, research analysts clearly believe Aurora Cannabis is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aurora Cannabis beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.

How does HLS Therapeutics compare to SugarBud Craft Growers?

SugarBud Craft Growers (CVE:SUGR) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

SugarBud Craft Growers has a beta of 2.768948, meaning that its stock price is 177% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 0.392903, meaning that its stock price is 61% less volatile than the S&P 500.

SugarBud Craft Growers has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft GrowersC$668.94M0.41C$12.12MC$1.686.83
HLS TherapeuticsC$55.50M2.65-C$15.53M-C$0.39N/A

SugarBud Craft Growers has a net margin of 2.11% compared to HLS Therapeutics' net margin of -22.34%. SugarBud Craft Growers' return on equity of 10.07% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SugarBud Craft Growers2.11% 10.07% 5.13%
HLS Therapeutics -22.34%-19.40%-2.89%

0.4% of SugarBud Craft Growers shares are held by institutional investors. Comparatively, 5.4% of HLS Therapeutics shares are held by institutional investors. 30.2% of SugarBud Craft Growers shares are held by insiders. Comparatively, 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, HLS Therapeutics had 2 more articles in the media than SugarBud Craft Growers. MarketBeat recorded 2 mentions for HLS Therapeutics and 0 mentions for SugarBud Craft Growers. HLS Therapeutics' average media sentiment score of 0.30 beat SugarBud Craft Growers' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
SugarBud Craft Growers Neutral
HLS Therapeutics Neutral

Summary

SugarBud Craft Growers beats HLS Therapeutics on 9 of the 13 factors compared between the two stocks.

How does HLS Therapeutics compare to Organigram?

HLS Therapeutics (TSE:HLS) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

HLS Therapeutics currently has a consensus target price of C$6.00, indicating a potential upside of 27.39%. Organigram has a consensus target price of C$3.13, indicating a potential upside of 65.34%. Given Organigram's stronger consensus rating and higher probable upside, analysts plainly believe Organigram is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Organigram
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

HLS Therapeutics has a beta of 0.392903, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.535528, meaning that its share price is 54% more volatile than the S&P 500.

HLS Therapeutics has higher earnings, but lower revenue than Organigram. HLS Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.50M2.65-C$15.53M-C$0.39N/A
OrganigramC$279.99M0.95-C$57.23MC$0.1512.27

Organigram has a net margin of 6.49% compared to HLS Therapeutics' net margin of -22.34%. Organigram's return on equity of 4.86% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-22.34% -19.40% -2.89%
Organigram 6.49%4.86%-5.56%

5.4% of HLS Therapeutics shares are held by institutional investors. Comparatively, 4.0% of Organigram shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Comparatively, 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, HLS Therapeutics had 2 more articles in the media than Organigram. MarketBeat recorded 2 mentions for HLS Therapeutics and 0 mentions for Organigram. HLS Therapeutics' average media sentiment score of 0.30 beat Organigram's score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
HLS Therapeutics Neutral
Organigram Neutral

Summary

Organigram beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -22.34%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-22.34% -19.40% -2.89%
Supreme Cannabis N/A N/A N/A

In the previous week, HLS Therapeutics had 2 more articles in the media than Supreme Cannabis. MarketBeat recorded 2 mentions for HLS Therapeutics and 0 mentions for Supreme Cannabis. HLS Therapeutics' average media sentiment score of 0.30 beat Supreme Cannabis' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
HLS Therapeutics Neutral
Supreme Cannabis Neutral

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.50M2.65-C$15.53M-C$0.39N/A
Supreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/A

Summary

HLS Therapeutics beats Supreme Cannabis on 6 of the 11 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HLS vs. The Competition

Export
MetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$147.30MC$1.63BC$6.25BC$11.72B
Dividend Yield4.30%2.97%2.73%6.22%
P/E Ratio-12.084.1829.0423.83
Price / Sales2.651,488.53476.4813.46
Price / Cash15.2210.3727.6282.69
Price / Book2.3910.729.674.48
Net Income-C$15.53MC$21.15BC$3.55BC$300.68M
7 Day Performance1.29%-1.16%1.70%0.12%
1 Month Performance7.05%0.17%5.62%2.88%
1 Year Performance10.30%24.19%34.42%57.78%

HLS Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
N/AC$4.71
flat		C$6.00
+27.4%		N/AC$147.30MC$55.50MN/A91
CPH
Cipher Pharmaceuticals
N/AC$17.71
-2.2%		N/AN/AC$447.73MC$50.45M16.875
ACB
Aurora Cannabis
2.0297 of 5 stars		C$4.67
+3.5%		C$9.25
+98.1%		N/AC$276.12MC$373.12MN/A1,073
SUGR
SugarBud Craft Growers
N/AC$11.47
flat		N/AN/AC$276.07MC$668.94M6.8344
OGI
Organigram
3.5773 of 5 stars		C$1.91
+2.7%		C$3.13
+63.6%		N/AC$268.62MC$279.99M12.40987

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel